UBS lowered the firm’s price target on Harmony Biosciences (HRMY) to $43 from $50 and keeps a Buy rating on the shares. Investor concerns over Harmony Biosciences have intensified following Zygel’s Phase 3 failure and the IH approval setback, while upcoming orexin agonists threaten Wakix’s market position, the analyst says.
Meet Your ETF AI Analyst
- Discover how TipRanks' ETF AI Analyst can help you make smarter investment decisions
- Explore ETFs TipRanks' users love and see what insights the ETF AI Analyst reveals about the ones you follow.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on HRMY:
- Harmony Biosciences price target lowered to $36 from $54 at Deutsche Bank
- Harmony Biosciences price target lowered to $35 from $50 at Mizuho
- Harmony Biosciences price target lowered to $55 from $70 at H.C. Wainwright
- Sell Rating for Harmony Biosciences: Setbacks in R&D and Uncertain Pipeline Outlook
- Harmony Biosciences Phase 3 Study Misses Endpoint